News | November 26, 2024
Merck announces pivotal phase 3 ZENITH trial evaluating WINREVAIR
WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality
